Harrow reported a $20 million loss for the first half of 2024, doubling from the previous year. Increased competition from generics and new drugs will squash margins. Harrow's recent strategy shift ...
Harrow, Inc.'s stock price has fallen due to disappointing earnings releases in Q1, Q2, and Q3 of 2023. The company's various revenue buckets have not performed as well as expected, leading to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results